NeoGenomics to Acquire Clarient, Broaden Cancer Diagnostics Portfolio

Cancer-focused genetic testing services provider NeoGenomics will acquire Clarient and its subsidiary Clarient Diagnostic Services. Clarient is a unit of GE Healthcare's Life Sciences business.

The transaction is valued at $80 million in cash, $110 million in preferred stock and 15 million shares of NeoGenomics common stock.

NeoGenomics will broaden its portfolio of cancer diagnostic tests with the purchase, including Clarient’s pathology services and capabilities in the analysis of solid tumor cancers of the breast, colon and lung.

Clarient has 415 employees and its revenues totaled $127 million in 2014. — Michael Cipriano